Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04878211 · ClinicalTrials.gov registry record · Phase 4
A Open-label Study to Assess Response to COVID-19 Vaccine in Multiple Sclerosis Participants Treated With Ofatumumab
A Phase 4 study, sponsored by Novartis Pharmaceuticals.
- Terminated
- Registry status
- Phase 4
- Development phase
- 24
- Enrollment target
NCT04878211 is a Phase 4 study that was terminated before completion, run by Novartis Pharmaceuticals. The registered enrollment target is 24 participants.
The verdict
NCT04878211, a Phase 4 study, was terminated before completion, sponsored by Novartis Pharmaceuticals.
- TERMINATED
- Registry status
- Phase 4
- Development phase
- 24 participants
- Enrollment target
Study Summary
This study evaluated if relapsing multiple sclerosis (MS) participants treated with ofatumumab 20 mg subcutaneous (s.c.) administered once monthly could develop an adequate immune response to the COVID-19 mRNA vaccine compared to participants on an interferon or glatiramer acetate.
Interventions
- DRUG Ofatumumab
- BIOLOGICAL mRNA COVID-19 vaccine
- DRUG interferon or glatiramer acetate
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2021-06-10 |
| Est. Completion | 2023-04-14 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04878211
The ClinicalTrials.gov registry entry for NCT04878211 describes a study currently listed as terminated, categorized as Phase 4. The registered enrollment target is 24 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novartis Pharmaceuticals, which has 1,375 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Ofatumumab is the first listed.
NCT04878211 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04878211 about?
NCT04878211 is a clinical study titled "A Open-label Study to Assess Response to COVID-19 Vaccine in Multiple Sclerosis Participants Treated With Ofatumumab". This study evaluated if relapsing multiple sclerosis (MS) participants treated with ofatumumab 20 mg subcutaneous (s.c.) administered once monthly could develop an adequate immune response to the COVID-19 mRNA vaccine compared to participants on an interferon or glatiramer acetate.
What is the current status of trial NCT04878211?
This trial is currently terminated. It is a Phase 4 study. The enrollment target is 24 participants. The study started on 2021-06-10. Estimated completion is 2023-04-14.
What interventions are being tested in trial NCT04878211?
The interventions under investigation include: Ofatumumab (DRUG), mRNA COVID-19 vaccine (BIOLOGICAL), interferon or glatiramer acetate (DRUG).
Who is sponsoring clinical trial NCT04878211?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.